UBS AM’s Protara Therapeutics TARA Stock Holding History

UBS AM’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.72K	Hold	451	–	–	﹤0.01%	3563
2026 Q1	$2.35K	Buy	+451	New	+$2.67K	﹤0.01%	3565

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

UBS AM's TARA Position: Q2 2026 in Review

UBS AM held its Protara Therapeutics (TARA) position steady in Q2 2026 at 451 shares worth $1.72K. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

UBS AM first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.35K in Q1 2026. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

UBS AM held 451 shares of Protara Therapeutics worth $1.72K as of Q2 2026.
UBS AM left its Protara Therapeutics share count unchanged in Q2 2026.
Protara Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3563 holding.
UBS AM first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
UBS AM's Protara Therapeutics position peaked at $2.35K in Q1 2026.
119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.